Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

173 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-15

Study Completion Date

2022-07-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The IN2COVID Study is a 2-staged phase I/II double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of AP-003 (Interferon α2b) when administered via inhalation twice daily for 10 days. Participants will have a final visit at Day 11.

A lead-in phase 1 substudy will be performed with at least 18 healthy adult male subjects to assess safety and tolerability of inhaled AP-003 compared to placebo for 10 days. Two cohorts of 9 subjects will be randomly assigned to receive two doses of inhaled AP-003 or placebo with an allocation ratio of 2:1. The first cohort will assess a dose of 2.5 MIU of inhaled AP-003. If no adverse events are observed, the second cohort will be conducted using a dose of 5 MIU of inhaled AP-003. Maximum tolerated dose will be determined in this phase 1 substudy.

After the completion of phase 1, the study will continue with a phase 2 treatment RCT in patients with COVID-19. In this phase, 150 adults with mild or moderate COVID-19 demonstrated by SARS-CoV-2 positive polymerase chain reaction (PCR) ≤ 5 days at enrollment will be randomized 1:1 (75 in each arm) to receive nebulized AP-003 or identical placebo twice daily during 10 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)

NCT04480138

Covid19

TERMINATED PHASE2

Intranasal INNA-051 for Prevention of COVID-19 in Adults

NCT05118763

COVID-19 Pandemic

WITHDRAWN PHASE2

First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.

NCT04535167

Viral Disease

COMPLETED PHASE1

Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients

NCT04293887

COVID-19 Recombinant Human Interferon α1β

UNKNOWN EARLY_PHASE1

Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19

NCT04732949

Severe Acute Respiratory Syndrome Coronavirus 2 COVID-19

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronavirus Disease 2019

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part 1a: Interferon alpha 2b 2.5 MIU

Nebulized interferon alpha 2b 2.5 MIU every 12 hours during 10 days (20 doses total)

Group Type EXPERIMENTAL

Interferon-Alpha2B

Intervention Type DRUG

Nebulized interferon alpha 2B

Part 1b: Interferon alpha 2b 5 MIU

Nebulized interferon alpha 2b 5 MIU every 12 hours during 10 days (20 doses total)

Group Type EXPERIMENTAL

Interferon-Alpha2B

Intervention Type DRUG

Nebulized interferon alpha 2B

Part 1: Placebo

Nebulized placebo every 12 hours during 10 days (20 doses total)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Nebulized placebo

Part 2: Interferon alpha 2b 5 MIU (or maximum tolerated dose from part 1)

Nebulized interferon alpha 2b 5 MIU (or maximum tolerated dose from part 1) every 12 hours during 10 days (20 doses total)

Group Type EXPERIMENTAL

Interferon-Alpha2B

Intervention Type DRUG

Nebulized interferon alpha 2B

Part 2: Placebo

Nebulized placebo every 12 hours during 10 days (20 doses total)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Nebulized placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Interferon-Alpha2B

Nebulized interferon alpha 2B

Intervention Type DRUG

Placebo

Nebulized placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AP-003

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male subjects aged 18-50 years;
2. In good state of health, determined by medical history, physical exam, and normal laboratory tests at screening;
3. Are able to provide informed consent for participation;
4. Are able and willing to comply with the study schedule and procedures.

1. Active SARS-CoV-2 infection demonstrated by positive polymerase chain reaction (PCR) ≤ 5 days at enrollment;
2. Symptomatic of mild or moderate COVID-19 for ≤ 5 days at enrollment. Symptoms can include fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, chest pain, with or without shortness of breath on exertion/dyspnea;
3. Age ≥ 18 years;
4. Are able to provide informed consent for participation;
5. Are able and willing to comply with the study schedule and procedures.

Exclusion Criteria

1. Active SARS-CoV-2 infection demonstrated by positive polymerase chain reaction (PCR) at enrollment;
2. Requiring CPAP for sleep apnea;
3. Pre-existing pulmonary disease;
4. Have any serious acute concomitant illness that, in the opinion of the investigator, would interfere with evaluation of safety of AP-003, or put the participant at risk of harm from study participation;
5. Are currently receiving an investigational agent, have participated in another study of an investigational agent within 30 days of enrollment, or were previously enrolled in the current study;
6. Are legally incompetent and unable to understand the study's purpose, significance, and consequences, and to make decisions accordingly;
7. Have known hypersensitivity to interferon alpha or any component of the study drug or placebo control.

Phase 2 stage:

1. Patients requiring CPAP for sleep apnea.
2. Patients with pre-existing pulmonary disease requiring chronic O2 supplementation.
3. Patients with known infection with Influenza A or B;
4. In the opinion of the Investigator, should undergo ventilatory (CPAP, mechanical ventilation, etc.) or circulatory support within 24 hours of study enrollment;
5. Have any serious acute concomitant illness that, in the opinion of the Investigator, would interfere with evaluation of safety or efficacy, or put the participant at risk of harm from study participation;
6. Are currently receiving an investigational agent, have participated in another study of an investigational agent within 30 days of enrollment, or were previously enrolled in the current study;
7. Are legally incompetent and unable to understand the study's purpose, significance, and consequences, and to make decisions accordingly;
8. Women who are pregnant or breast-feeding, or planning to conceive in the next 30 days;
9. Have known hypersensitivity to interferon alpha or any component of the study drug or placebo control.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes